| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | JUNO THERAPEUTICS INCORPORATED | 1,229,512 | 46,832,000 | 32.48% | ||
| 2 | PARATEK PHARMACEUTICALS INC | 2,138,872 | 32,447,000 | 22.51% | ||
| 3 | Egalet Corp | 2,814,928 | 19,310,000 | 13.39% | ||
| 4 | FIBROGEN INC COM | 822,175 | 17,504,000 | 12.14% | ||
| 5 | Nabriva Therapeutics AG | 1,145,890 | 10,267,000 | 7.12% | ||
| 6 | ESSA Pharma | 1,696,969 | 5,515,000 | 3.83% | ||
| 7 | Pieris Pharmaceuticals | 2,483,949 | 4,720,000 | 3.27% | ||
| 8 | EDITAS MEDICINE INCORPORATED | 105,007 | 3,627,000 | 2.52% | ||
| 9 | Proteon Therapeutics | 250,000 | 1,935,000 | 1.34% | ||
| 10 | Dicerna Pharmaceuticals | 223,457 | 1,198,000 | 0.83% | ||
| 11 | CymaBay Therapeutics | 606,100 | 818,000 | 0.57% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-16-016121, filed 2016.05.02).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
